Thomas J. Schuetz, MD, PhD has over 20 years of experience in oncology, biopharmaceutical drug development, and life science venture investing. He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. While at OrbiMed, Thomas also co-founded Audentes Therapeutics, where he served as a director until its acquisition by Astellas. While at OrbiMed, he worked on the investments in Enobia Pharma, Relypsa, and Arteaus Therapeutics, and served as a director at each of those companies. Thomas has multiple years of clinical strategy, development, and operations experience, including roles as chief medical officer of Therion Biologics Corporation, a cancer vaccine company, and as vice president of clinical affairs at Transkaryotic Therapies, a company acquired by Shire.
Thomas completed his medical training at Massachusetts General Hospital, where he served as the chief medical resident. He completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Thomas holds a BS in chemistry and a MD from Harvard Medical School, and a PhD in genetics from Harvard University. Thomas is board certified in medical oncology.